05/142025
Company
First patient dosed in the Phase 3 RASolve 301 trial
RASolve 301, the Phase 3 trial of daraxonrasib versus docetaxel in previously treated RAS-mutant non-small cell lung cancer, has begun and plans to enroll approximately 420 patients.
Source: Revolution Medicines